fbpx

molecules of the month

MLi-2

oral, brain-penetrant LRRK2 kinase inhibitor

recapitulated LRRK2 lung tox. in model

discovery details manuscript in preparation

J. Pharmacol. Exp. Ther., Jan. 28, 2021

Merck & Co., Inc., Boston, MA

Chemical structure of molecule MLi-2 inhibitor
1 min read

The Merck LRRK2 inhibitor, MLi-2, is an orally available tool compound that is structurally distinct from the LRRK2 inhibitor GNE-7915. LRRK2 had been a highly attractive target for treating Parkinson’s disease, but pulmonary toxicity observed with LRRK2 inhibition in non-human primates (NHP) cast a shadow on the utility of LRRK2 inhibitors. Since NHP studies are cost and resource-intensive, it was difficult to study the toxicity in depth. The Merck team was able to recapitulate the pulmonary toxicity in rodents with MLi-2, and found that the lung effects were due to chronic LRRK2 inhibition and were mild and readily reversible. This study provides a higher-throughput method to assess new LRRK2 inhibitor scaffolds and more broadly understand on-target effects of LRRK2 inhibition.


request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.


already a member? log in: